A Study of Paliperidone Palmitate 6-Month Formulation
Condition: Schizophrenia Interventions: Drug: PP6M 700 mg eq.; Drug: PP6M 1000 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: PP1M; Other: Placebo Sponsor: Janssen Research & Development, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2017 Category: Research Source Type: clinical trials
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
Condition: Schizophrenia Interventions: Combination Product: Aripiprazole Lauroxil; Drug: Paliperidone Palmitate Sponsor: Alkermes, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2017 Category: Research Source Type: clinical trials
A Study of Paliperidone Palmitate 6-Month Formulation
Condition: Schizophrenia Interventions: Drug: PP6M 700 mg eq.; Drug: PP6M 1000 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: PP1M; Other: Placebo Sponsor: Janssen Research & Development, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2017 Category: Research Source Type: clinical trials
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
Condition: Schizophrenia Interventions: Combination Product: Aripiprazole Lauroxil; Drug: Paliperidone Palmitate Sponsor: Alkermes, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2017 Category: Research Source Type: clinical trials
A Study of Paliperidone Palmitate 6-Month Formulation
Condition: Schizophrenia Interventions: Drug: PP6M 700 mg eq.; Drug: PP6M 1000 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: PP1M; Other: Placebo Sponsor: Janssen Research & Development, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2017 Category: Research Source Type: clinical trials
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
Condition: Schizophrenia Interventions: Combination Product: Aripiprazole Lauroxil; Drug: Paliperidone Palmitate Sponsor: Alkermes, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2017 Category: Research Source Type: clinical trials
A Study of Paliperidone Palmitate 6-Month Formulation
Condition: Schizophrenia Interventions: Drug: PP6M 700 mg eq.; Drug: PP6M 1000 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: PP1M; Other: Placebo Sponsor: Janssen Research & Development, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2017 Category: Research Source Type: clinical trials
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
Condition: Schizophrenia Interventions: Combination Product: Aripiprazole Lauroxil; Drug: Paliperidone Palmitate Sponsor: Alkermes, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2017 Category: Research Source Type: clinical trials
A Study of Paliperidone Palmitate 6-Month Formulation
Condition: Schizophrenia Interventions: Drug: PP6M 700 mg eq.; Drug: PP6M 1000 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: PP1M; Other: Placebo Sponsor: Janssen Research & Development, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2017 Category: Research Source Type: clinical trials